HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors

HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors

IntroductionNeuroendocrine neoplasms (NENs) are a rare group of tumors exceptionally heterogeneous, with clinical presentation ranging from well differentiated more indolent tumors to poorly differentiated very aggressive forms. Both are often diagnosed after the metastatic spread and require approp...

Full description

Bibliographic Details
Main Authors: Chiara Liverani, Chiara Spadazzi, Toni Ibrahim, Federica Pieri, Flavia Foca, Chiara Calabrese, Alessandro De Vita, Giacomo Miserocchi, Claudia Cocchi, Silvia Vanni, Giorgio Ercolani, Davide Cavaliere, Nicoletta Ranallo, Elisa Chiadini, Giovanna Prisinzano, Stefano Severi, Maddalena Sansovini, Giovanni Martinelli, Alberto Bongiovanni, Laura Mercatali
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Endocrinology
Subjects:
nen
primary cultures
Lenvatinib efficacy
HRAS overexpression
predictive marker
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.1045038/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.1045038/full

Similar Items